Letters, Statements & Analysis

AMCP communicates the importance of managed care pharmacy by collaborating with members to provide comments, analysis, and testimony to Congress and federal and state agencies on the impact of proposed regulations and laws on managed care pharmacy and patients.

AMCP Summary: Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals

On January 31, 2019 the Department of Health and Human Services (HHS) proposed sweeping changes to the current system for medication pricing and contracting by pharmacy benefit management (PBM) companies in federal programs--namely Medicare Part D and Medicaid programs.

AMCP Joins 50 Other Organizations in Support of the Reintroduction of the CREATES Act

The CREATES Act is a bipartisan, market-based solution to increase competition and thus lower prescription drug prices for patients and consumers. This reform helps speed the introduction of generic and biosimilar medicines by facilitating the purchase of brand name drug samples on market-based terms from pharmaceutical companies who otherwise would use anticompetitive tactics to block access.

AMCP Summary- Advance Notice of Methodological Changes for Calendar Year (CY) 2020 for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 2020 Draft Call Letter

On January 30, 2019, the Centers for Medicare and Medicaid Services (CMS) published an Advanced Notice of Methodological Changes for Calendar Year (CY) 2020 for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 2020 Draft Call Letter, known as the “ draft Call Letter.” The draft Call Letter outlines payment amounts for beneficiary cost sharing, risk corridors for Part C and Part D plans, and beneficiary payments for calendar year 2020.

On January 28, AMCP submitted comments to HHS and ONC on the HHS Draft Strategy on Reducing Regulatory and Administrative Burden to the Use of Health IT and EHRs

The Academy of Managed Care Pharmacy (AMCP) appreciates the opportunity to provide comments to the Centers for Medicare and Medicaid Services (CMS) and the Office of the National Coordinator for Health Information Technology (ONC) in response to the draft Strategy on Reducing Burden Relating to the Use of Health IT and EHRs.

AMCP Submits Comments to CMS on Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses Proposed Rulemaking

The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare & Medicaid Services (CMS) for the opportunity to provide comments in response to the proposed rule “Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses [CMS-4180-P]” published in the Federal Register on November 30, 2018.

AMCP submits comments to CMS on Medicare and Medicaid Programs; Policy and Technical Changes to the Medicare Advantage, Medicare Prescription Drug Benefit, Program of All-Inclusive Care for the Elderly (PACE) Medicaid Fee-for-Service, and Medicaid Managed

The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare & Medicaid Services (CMS) for the opportunity to provide comments in response to the proposed rule “Medicare and Medicaid Programs; Policy and Technical Changes to the Medicare Advantage, Medicare Prescription Drug Benefit, Program of All-Inclusive Care for the Elderly (PACE), Medicaid Fee-for-Service and Medicaid Managed Care Programs for Years 2020 and 2021 [CMS-4185-P]” published in the Federal Register on November 1, 2018.
Legislation & Regulation

AMCP Summary – Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses

On November 26, The Centers for Medicare and Medicaid Services (CMS) issued a new proposed rule outlining potential policies that are intended to lower the cost of prescription drugs through tools that allow prescription drug plans to negotiate prices and by improving access to costly drugs through reduction of out-of-pocket costs for beneficiaries.